Clinical Trial Update: Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rifaximin SSD to delay hepatic encephalopathy decompensation in cirrhosis is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Encephalopathy

Drugs mentioned

• Rifaximin SSD (rifaximin)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Hepatic Encephalopathy | Phase 3 | Status: ACTIVE_NOT_RECRUITING